United Therapeutics Corp (NASDAQ: UTHR) exceeded expectations in their fourth-quarter earnings report, revealing earnings of $7.70 per share, surpassing the estimated $7.09 per share. However, the company fell short of the projected $813.077 million in quarterly sales with reported sales totaling $790.200 million. Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics, expressed gratitude towards the team for achieving record total revenue for the fourth consecutive year. The company is eagerly anticipating the results of their ADVANCE OUTCOMES and TETON-1 clinical programs which have the potential to introduce new treatment alternatives for patients.